Premium Nahrungsergänzungsmittel | artgerecht

Lipoprotein Lipase (LPL) – Function and Importance

Lipoprotein lipase (LPL) is a key enzyme in fat metabolism that breaks down triglycerides from the bloodstream, supplying muscles and fatty tissue with energy.

Regular tips about health Regular tips about health

Things worth knowing about "Lipoprotein Lipase"

Lipoprotein lipase (LPL) is a key enzyme in fat metabolism that breaks down triglycerides from the bloodstream, supplying muscles and fatty tissue with energy.

What is Lipoprotein Lipase?

Lipoprotein lipase (LPL) is an enzyme that plays a central role in the human fat metabolism. It is primarily anchored on the inner surface of blood vessel walls (endothelium) in muscle tissue, cardiac muscle, and adipose (fat) tissue. Its main function is to break down triglycerides – fats transported in lipoproteins such as VLDL (Very Low-Density Lipoprotein) and chylomicrons – into free fatty acids and glycerol. These products are then taken up by surrounding cells either as an energy source or for fat storage.

Mechanism of Action

Lipoprotein lipase is produced in various tissues, predominantly in adipose tissue, skeletal muscle, and cardiac muscle, and is subsequently transported to the surface of capillary endothelial cells. There, it binds to heparan sulfate proteoglycans, which serve as anchors. When triglyceride-rich lipoproteins (TRL) – namely VLDL and chylomicrons – flow past the vessel wall, LPL binds to these particles and hydrolyzes the triglycerides they contain. The resulting free fatty acids diffuse directly into adjacent tissue:

In muscle tissue, they are used for energy production (beta-oxidation).
In adipose tissue, they are re-esterified and stored as triglycerides.
In the cardiac muscle, they serve as an important energy carrier for continuous heart function.

Regulation of Lipoprotein Lipase

The activity of LPL is precisely regulated by various hormonal and metabolic signals:

Insulin increases LPL activity in adipose tissue, promoting fat storage after a meal.
Fasting and physical activity increase LPL activity in muscle tissue to provide more fatty acids for energy.
Apolipoprotein C-II (ApoC-II) is an essential cofactor for LPL – without this protein, the enzyme is nearly inactive.
Apolipoprotein C-III (ApoC-III) and angiopoietin-like proteins (ANGPTL3, ANGPTL4, ANGPTL8) inhibit LPL activity and play an important role in tissue-specific regulation.

Clinical Significance

LPL Deficiency (Hyperlipoproteinemia Type I)

Congenital LPL deficiency (also known as familial chylomicronemia or hyperlipoproteinemia type I) is a rare, autosomal recessively inherited disorder. Affected individuals are unable to adequately break down dietary fats, resulting in extremely elevated blood triglyceride levels (hypertriglyceridemia). Typical complications include:

Recurrent, often severe pancreatitis (inflammation of the pancreas)
Xanthomas (yellowish fat deposits in the skin)
Lipemia retinalis (visible discoloration of retinal blood vessels)
Hepatosplenomegaly (enlargement of the liver and spleen)

LPL Variants and Cardiovascular Risk

Certain genetic variants (polymorphisms) in the LPL gene can increase or decrease enzyme activity, thereby influencing an individual risk for cardiovascular disease. Higher LPL activity is often associated with lower triglyceride levels and higher HDL cholesterol levels – both favorable factors for heart health.

LPL in Obesity and Metabolic Syndrome

In obesity and metabolic syndrome, the balance of LPL activity between adipose tissue and muscle tissue is disrupted. This contributes to increased fat storage, elevated triglyceride levels, and an increased cardiovascular risk.

Diagnosis and Treatment

The diagnosis of LPL deficiency is made by measuring blood triglyceride levels, through specific enzyme activity tests (post-heparin plasma lipase activity), and genetic testing. Treatment of LPL deficiency is primarily based on a severely fat-restricted diet. Since 2012, Europe had access to alipogene tiparvovec (Glybera), the first approved gene therapy for LPL deficiency; however, it was withdrawn from the market due to extremely high costs and rare use. Newer therapeutic approaches such as volanesorsen (an antisense oligonucleotide targeting ApoC-III) show promising results in treating severe hypertriglyceridemia.

References

Nordestgaard, B.G. et al. (2020). Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at-risk individuals. European Heart Journal, 37(25), 1944–1953.
Brahm, A.J. & Hegele, R.A. (2015). Chylomicronaemia – current diagnosis and future therapies. Nature Reviews Endocrinology, 11(6), 352–362.
Wang, H. & Eckel, R.H. (2009). Lipoprotein lipase: from gene expression to direct function in the artery wall. Trends in Endocrinology and Metabolism, 20(9), 465–473.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.